Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD ...
Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD upfront payment, potential milestones of ...
Making civics class relate more to students' lives is working in some US schools and could be fresh approach needed in NC.
OTTAWA — Ontarians can expect a rash of new rules, laws and regulations coming up in 2026. Starting Jan. 1, carbon monoxide ...
SuFu Creative, a nonprofit focused on community art and charitable events, will close and merge with Zenith Art Studios in ...
BARRACKS AND STRATEGYThe AFP celebrated its 90th foundation anniversary last Dec. 19, 2025, with the theme “AFP @90, Matatag sa Paglilingkod sa Bayan” ...
NVIDIA announced DLSS 4.5, G-SYNC Pulsar monitors availability, RTX Remix Logic, new ACE tech integrations, NVIDIA App updates, nre DLSS 4 titles, more devices and ways to play with GeForce NOW, and ...
Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...
President Trump said the U.S. Navy would build a new ‘Trump-class’ battleship, with construction of the first ship to begin almost immediately. Photo: Alex Brandon/Associated Press President Trump ...
Vietnam Investment Review on MSN
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback